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Abstract
This is a prospective, hospital-based study reporting an update and the preva-
lence of nonconvulsive status epilepticus (NCSE) in patients with altered mental 
status (AMS) in Qatar. Patients presenting with NCSE are compared to controls. 
Two-hundred and fifty patients with AMS are involved. Patients with NCSE are: 
65 (12–79 years, m, 37, f, 28); controls: 185 (12–80 years, m, 101, f, 84). Occurrence 
of NCSE in patients with AMS was 26%. NCSE patients were younger than con-
trols (p < 0.001). Deaths in the NCSE group occurred in 31% and 19% in controls 
(p < 0.0007). Hospitalization length was longer in NCSE proper and in comatose 
NCSE compared to controls (p < 0.02, p < 0.03). Recovery occurred in 40% of 
NCSE patients and 53% of controls (p < 0.08). About 31% of patients (n = 21) 
had refractory NCSE and 9 died. This is the first study reporting the prevalence of 
NCSE in Qatar. This prevalence (26%) is in the middle range. NCSE did not do bet-
ter than the controls, result being disappointing regarding comatose NCSE. NCSE 
is an emerging condition requiring rapid diagnosis and rapid treatment. Regarding 
the optimal duration of continuous EGG (cEEG) monitoring to diagnose the major-
ity of NCSE cases, 3 days of cEEG monitoring could accomplish this task.
Keywords: nonconvulsive seizures, nonconvulsive status epilepticus,  
epidemiology, treatment, antiseizure medications, outcome
1. Introduction
Nonconvulsive status epilepticus (NCSE) is accompanied with an altered men-
tal status (AMS) without convulsive motor activity [1]. Because of the paucity of 
clinical symptoms, EEG is mandatory for the diagnosis of NCSE. In the intensive 
care unit (ICU), where the patient is often obtunded/comatose, cEEG monitoring is 
required to reveal NCSE. cEEG monitoring is important because of the difficulty dis-
tinguishing when AMS and coma are ictal and differentiating them from non-ictal 
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symptoms associated with underlying pathology such as posthypoxic, metabolic or 
septic encephalopathies, and the effects of sedative drugs. Furthermore, the diagno-
sis of NCSE is frequently delayed, with patients in the ICU having often other serious 
medical conditions. To diagnose NCSE a high degree of suspicion is required [2], 
and consequently NCSE remains unrecognized. Table 1 shows how frequently the 
diagnosis of NCSE could be missed in the emergency room.
In the United States, the estimated incidence of status epilepticus (SE) is 
15–20/100,000 cases per year [3], and NCSE is representing 63% of all SE [4]. Both 
nonconvulsive seizures (NCS) and NCSE occur very frequently in the ICU and 
emergency department (ED): NCSs/NCSE is recorded in 8% to 48% in ICU patients 
[5–8], many of which are fatal [9–11].
Prevalence of NCSE is reported from different geographical areas of the world in 
patients with AMS [12–16]; However, to our knowledge, there is no study reporting the 
frequency of NCSE in the Middle East and North Africa (MENA) region; in this vast 
geographic area, the only NCSE incidence/prevalence is described from the MENA’s 
neighboring countries like Pakistan, India, Turkey, and Israel [17–21]. There is a need 
for studies regarding the prevalence and morbidity of NCSE in MENA countries [22].
There is also a lack of consensus regarding the EEG monitoring duration when 
looking for NCSE in ICU patients with AMS; the authors dealing with this issue 
report a considerable variation in the duration of cEEG monitoring [23–26].
The aims of this chapter are multiple:
a. Know the rate of occurrence of NCSE in patients with AMS admitted to Hamad 
General Hospital (HGH) Doha, Qatar, using cEEG monitoring.
b. Describe the clinical and EEG findings, causes, head CT/MRI, as well as the 
treatment and outcomes of NCSE in patients with AMS, and compare the 
results to a matched control group with similar clinical presentations of AMS.
c. Highlight and discuss the lack of consensus in the literature regarding the dura-
tion of cEEG monitoring while looking for NCSs/NCSE in patients with AMS.
2. Methods
This clinical study was performed according to the Good Clinical Practice (GCP) 
guidelines. Approval was obtained from Hamad Medical Corporation Ethical 
Committee and Institutional Review Board (IRB). All subjects/relative(s) (caregivers) 
provided consent before participating.
Lethargy and confusion attributed to a postictal state
Ictal confusion mistaken for metabolic encephalopathy
Unresponsiveness and catalepsy presumed to be psychogenic
Obtundation thought to be due to alcohol or drug intoxication
Hallucinations and agitation mistaken for psychosis or delirium
Lethargy presumed secondary to hypoglycemia
Mutism attributed to aphasia
Laughing and crying ascribed to emotional lability
Table 1. 
Examples of delayed or missed NCSE diagnosis; from Kaplan [48].
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2.1 Definition of NCSE and AMS
NCSE was defined as an AMS with diminished responsiveness, a positive EEG. 
and a response to anti-seizure drug (ASD) therapy; as a status, NCSE should be 
present for a minimum of 30 minutes of continuous nonconvulsive seizure activity 
or after repeated seizures without recovery of consciousness between events [1]; 
recently shorter durations have been reported.
Young’s criteria [27] of electrographic SE and modified criteria of Chong and 
Hirsch [28] were used to diagnose NCSE; In addition, the International League 
against Epilepsy (ILAE) definition and classification of Status Epilepticus [29] and 
EEG Salzburg Consensus Criteria for NCSE [30] were used to recognize NCSE; NCSE 
was diagnosed in the presence of continuous generalized spike wave discharges with 
changes in intensity or frequency, epileptiform activity with ictal patterns that wax 
and wane, rhythmic and periodic discharges, and subtle and discrete electrographic 
seizures, when lasting for 30 minutes [10, 13, 15]. In comatose patients, epileptiform 
discharges faster than 2.5 Hz or generalized periodic discharges (GPDs), lateralized 
periodic discharges (LPDs) and continuous 2/s GPDs with triphasic morphology [31] 
of less than 2.5 Hz, as well as rhythmic discharges (RDs) faster than 0.5 Hz were also 
taken into consideration as NCSE if they responded to benzodiazepine treatment with 
improvement in the EEG or in patient mental status [13, 15, 29, 32].
Two EEG specialists agreed independently that the patient condition and EEG 
findings represent NCSE particularly when an EEG pattern did not meet above cri-
teria; finally NCSE was considered if the EEG/or level of consciousness responded 
to an ASD trial.
Unexplained confusional state, change in behavior, mild to moderate obtundation, 
alteration in cognition and behavior from baseline, and unexplained decrease in level 
of consciousness including after convulsive status epilepticus treatment [2, 33] were 
considered AMS; in elderly patients, delirium (altered level of consciousness, with a 
fluctuating course, disorganized thinking, and inattention) was also included [15].
2.2 Patient selection for cEEG monitoring
All patients with AMS, from the Emergency Department and from ICUs, aged 
12 years or above, had a cEEG monitoring [2, 33]. Not included were patients with 
open head injury, those whose relatives did not sign the consent form and patients 
with suspected brain death and an isoelectric EEG. In addition, patients treated for 
convulsive status epilepticus (CSE) who did not develop later NCSs/NCSE on cEEG 
monitoring were excluded.
2.3 Patients with NCSE and control group
Patients with AMS and those whose EEG was not compatible with NCSE during 
3 days of cEEG monitoring recording were taken as controls. The NCSE and control 
groups were compared: this included the clinical presentation and medical condition, 
AMS etiology, neuroimaging, laboratory findings, length of stay, recovery, and outcome
2.4 cEEG monitoring and duration
2.4.1 cEEG recording
The following EEG recording system was used: international 10/20 system with 
21 silver/silver chloride cup electrodes. Digital EEG signal stored electronically was 
filtered for display. High-pass filter and low-pass filter were 0.5–1 and 70 Hz. For 
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extraneous electrical artifact, 50 Hz notch filter was used; impedance was 100 and 
5000 ohms. cEEG was done by EEG technologists and monitored at least twice a 
day by an EEG specialist.
2.4.2 EEG duration
The duration of cEEG monitoring was determined by the response to treatment 
of NCSs/NCSE, the presence of other EEG features like rhythmic and periodic 
discharges, and their responses to treatment.
2.5 Laboratory investigations and Neuroimaging
The following investigations were performed in most NCSE cases and controls: 
complete blood count, electrolytes, liver and renal functions, brain MRI, and/or CT 
head; imaging was performed either before or after cEEG monitoring
2.6 NCSs/NCSE treatment
Benzodiazepines (lorazepam or diazepam) were used when NCSs/NCSE was 
suspected. If seizures persisted, European Federation of Neurological Sciences 
(EFNS) Guidelines and Glauser et al. report on NCSE treatment were followed: IV 
diazepam or lorazepam first and then second-line ASDs were initiated—valproic 
acid, phenytoin, or levetiracetam. If no results, continuous infusions of propofol, 
midazolam, and barbiturates were used [34, 35].
Many patients received more than one ASD. refractory NCSE was treated with 
anesthetic agents; same treatment protocol was followed in comatose NCSE. ASDs 
were not used in control group.
2.7 Outcome parameters
Seizure control and survival/death were considered as primary outcome 
parameters, while complete recovery and length of stay were secondary outcome 
parameters.
2.8 Statistical methods
Descriptive statistics (mean with standard deviation) for continuous variables, 
frequency, and percentages for categorical variables was used; differences between 
mean levels of NCSE and controls, outcome and morbidity, and Student’s t-test were 
calculated; to detect associations between categorical variables and NCSE vs controls, 
outcome, and morbidity, chi-square tests or Fisher’s exact tests were used. For indepen-
dent variables at univariate analysis, NCSE logistic regressions were performed using 
a significance level of 0.05. A P value of 0.05 (two tailed) was considered a statistically 
significant level. For statistical analysis, an SPSS 22.0 statistical software was used.
3. Results
3.1 Occurrence of NCSE
Six patients suffered from CSE; only one of them who showed later NCSE EEG 
features and was included in the study. Twenty patients presented NCSs; 30% of 
them (n = 6) responded to ASDs and did not develop NCSE on cEEG monitoring; 
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they were also excluded from the study; the rest (70%, n=14) developed later NCSE 
during cEEG monitoring. These patients were included in the study.
NCSE group: 250 patients with AMS or coma underwent cEEG monitoring. 
Sixty-two patients were excluded (see reasons above and patient selection). In total, 
65 patient responded to the criteria of NCSE (Table 2). The occurrence rate of 
NCSE was 65/250 (26%).
3.2 Characterization of NCSE and the control group
The control group consisted of 185 patients with AMS or coma in which cEEG 
monitoring did not show any features of NCSE. Table 2 shows the demographic and 
clinical features of NCSE and control subjects. Only age and presence of subtle motor 
phenomena differed between the two groups; the NCSE patients were relatively 
younger and displayed subtle motor phenomena more often. As for etiology and 
comorbid states, a history of previous seizures and presence of cortical dysplasia 
were significantly more common in the NCSE group (Table 3). Other etiologies were 
not informative. Head injury, stroke, and status postcardiac arrest were frequently 
encountered in accident and emergency patients with NCSE; CT head done in 52 
Variable NCSE (n 65) Controls (n 185) P value
Age 45.7 ± 19 52.3 ± 15.8 0.001
Gender M = 37/F = 28 M = 101/F = 84 0.75
Unresponsive/somnolent 11 (17%) 46 (25%) 0.19
Acute confusion 7 (11%) 18 (10%) 0.81
Severely decreased level of consciousness 20 (31%) 61 (33%) 0.74
Stupor/coma 27 (42%) 60 (32%) 0.23
Subtle motor phenomena 12 (18%) 8 (4%) 0.001
Note: P values are calculated using Chi-square tests and student t tests wherever appropriate.
Table 2. 
Characteristics of patients with NCSE and controls.
Variable NCSE (n 65) Controls (n 185) P value
Stroke (hemorrhagic, ischemic, subarachnoid 
hemorrhage)
16 (25%) 67 (36%) 0.09
Status post cardiac arrest 15 (23%) 35 (19%) 0.59
Head injury 8 (12%) 34 (18%) 0.34
Previous seizures (uncontrolled) 12 (18.4%) 4 (2%) 0.001
Cortical dysplasia 3 (4.6%) 0 0.02
Sepsis 3 (4.6%) 7 (3.8%) 1.00
Hepatic encephalopathy 1 (1.5%) 3 (1.6%) 1.00
End stage renal disease, post renal transplant 2 (3%) 11 (6%) 0.37
Intoxications 0 8 (4.3%) 0.12
Hypertensive encephalopathy 1 (1.5%) 6 (3.2%) 0.68
Personality disorder 1 (1.5%) 3 (1.6%) 1.0
Unknown 3 (4.6%) 7 (3.8%) 1.0
Note: P values are calculated using Chi-square tests or Fisher’s exact test wherever appropriate.
Table 3. 
Etiology of patients with NCSE and controls.
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NCSE cases and in 101 of controls and MRI head done in 41 NCSE cases and in 97 of 
controls showed hippocampal sclerosis, malformations of cortical development, and 
encephalomalacia, which were more commonly seen in the NCSE group (Table 4).
Abnormal cholesterol and liver enzymes were more often abnormal in the NCSE 
group than controls (NCSE 15%, controls 4%, p 0.004).
3.3 Length of cEEG monitoring and time of occurrence of NCSs/NCSE
Twenty patients showed NCSs; 65% of them (n = 13) had NCSs during the first 
40 minutes of recording, whereas 35% (n = 7) had their seizures later but within the 
first 48 hours of cEEG monitoring.
In the NCSE group (n = 65), NCSE EEG patterns were recorded during the first 
3 hours in 66% (n = 43), later but within the first 48 hours in 22% (n = 14), and in 
the third day in 12% (n = 8). Among the 22 patients with late NCSE, 17 (77%) were 
comatose.
3.4 NCSE proper and comatose NCSE
The NCSE group was further subdivided into two: NCSE proper without coma 
(n = 39) and comatose NCSE (n = 26) [32, 36]; NCSE proper is defined as clinical 
symptoms suggestive of SE with mild impairment of consciousness (absence status or 
complex focal SE); NCSE with coma-lateralized epileptiform discharges, NCSE with 
coma-generalized epileptiform discharges is defined as deep coma of various etiology 
with characteristic epileptiform EEG pattern but with no clinical motor signs of SE; 
NCSE proper patients are significantly younger than the comatose NCSE ones  
(Table 5). NCSE in comatose patients was often recorded after the first day of cEEG 
monitoring: during the first 24 hours in only 54% (n = 14/26), later but within 48 hours 
in 35% (n = 9/26), and in the third day in 11% (n = 3/26) of the patients; comparatively, 
NCSE proper was recorded during the first day in 77% (n = 30/39), later but within 48 
hours in 10% (n = 4/39), and during the third day in 13% (n = 5/39) of patients.
The 14 patients with early comatose NCSE (first 24 hs) suffered from head 
injury (n = 4), stroke (n = 4), and cardiac arrest (n = 3); and no etiology was found 
in three patients; comparatively, in the NCSE proper group (n = 30), 18 patients 
suffered from previous seizures, 5 from stroke, 3 from sepsis, 2 from head injury, 
and 2 from cardiac arrest.
Variable CT (n pts) MRI (n pts)
NCSE  
(n 52)
Controls  
(n 101)
P 
value
NCSE  
(n 41)
Controls  
(n 97)
P value
Abnormal 32 (62%) 49 (49%) 0.17 33 (80%) 53 (55%) 0.01
Ischemia, intracerebral hemorrhage, 
subarachnoid & subdural hemorrhage
14 (27%) 18 (18%) 0.21 16 (39%) 32 (33%) 0.56
Cortical atrophy 5 (10%) 10 (10%) 1.0 3 (7%) 6 (6%) 1.0
Polymicrogyria, cortical dysplasia, 
heterotopia
3 (7%) 0 0.02
Hippocampal sclerosis 3 (6%) 0 0.04 3 (7%) 1 (1%) 0.08
Encephalomalacia 3 (7%) 10 (10%) 0.04
Meningeal/cortical enhancement 1 (2%) 2 (2%) 1.0 1 (2%) 2 (2%) 1.0
Note: P values are calculated using Chi-square tests or Fisher’s exact test wherever appropriate.
Table 4. 
Head CT and MRI findings (some patients had both CT and MRI).
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3.5 Antiseizure drug (ASD) treatment
Patients with NCSs (n = 20) were treated as follows: 18 with benzodiazepines, 10 
with valproate IV, and 8 with levetiracetam plus valproate IV. The 65 NCSE patients 
received the following: lorazepam 4–8 mg IV or diazepam 10 mg IV (n = 45), 
levetiracetam IV or PO (n = 22), phenytoin IV (n = 21), valproate IV or PO (n = 18), 
topiramate PO (n = 5), phenobarbitone IV (n = 7), midazolam IV (n = 15), propofol 
(n = 5), fentanyl (n = 2), and thiopental (n = 3).
3.6 Outcome
3.6.1 Primary outcome
NCSE group (n = 65): 69% (n = 45, m 25, f 20) responded to treatment within 
48 hours, whereas 31% (n = 20, m 12, f 8) died.
Control group (n = 185): 19% (n = 35, m 20, f 15) died. Thus, compared to the 
control group, death was more frequent in the NCSE group; there was additional 
statistical significance when NCSE proper was compared to comatose NCSE and 
when comatose NCSE was compared to controls (Table 5), with comatose patients 
exhibiting a more ominous outcome. The majority of patients with early occurrence 
of NCSs/NCSE = 65% (40 minutes to 3 hours) died (n = 13/20). Causes of death 
in NCSE (n = 20) group were distributed as follows: cardiac arrest (n = 6), hemor-
rhagic and ischemic strokes (n = 5), sepsis (n = 3), head injury (n = 4), subarach-
noid hemorrhage (n = 1), and cerebral abscess (n = 1).
3.6.2 Secondary outcome
Compared to controls, NCSE achieved complete recovery in 40% (n = 26, m 15, 
f 11) compared to controls 53% (n = 98, m 55, f 43); Table 5 shows that this achieved 
statistical significance when comatose NCSE was compared to controls; NCSE group 
(NCSE proper plus comatose NCSE) had a longer hospital stay than the controls.
Variable NCSE (n 65) NCSE proper 
(=without coma) 
(n 39)
NCSE with coma 
(n 26)
Control  
(n 185)
P value
Deaths 20 (31%) 8 (21%)* 12 (46%)*§ 35 (19%) § * 0.05, § 
0.0007
Gender male 37 (57%) 23 (59%) 14 (54%) 101 (55%)
Age (years) 45.7 ± 19§ 36.9 ± 24& 51.3 ± 16.9& 52.3 ± 15.8 § § 0.001, & 
0.006
Hospital stay 
(days)
15.2 ± 7.7# 14.6 ± 7.8 16.4 ± 7.7^ 12.7 ± 5.5#^ # 0.02, 
^0.03
Complete 
recovery
26 (40%) 18 (46%) 8 (31%)a 98 (53%)a a 0.04
Note: P values are calculated using Chi-square tests, Fisher exact tests and Student t tests wherever appropriate.
* and § compare Death occuring respectively in NCSE without coma to NCSE with coma and also Death occurring in 
NCSE with coma to controls (respectively 0.05 and 0.0007).
§ and & compare patients and controls ‘s age respectively in NCSE group to controls and also in NCSE without coma 
to NCSE with coma (respectively 0.001 and 0.006).
# and ^ compare hospital stay respectively in NCSE group to controls and also in NCSE with coma to controls 
(respectively 0.02 and 0.03); symbol a compares complete recovery in NCSE with coma to controls (0.04)
Table 5. 
Occurrence and comparison of the listed variables in the NCSE groups and control group.
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Figure 1. 
(a) EEG shows left LPDs; patient received 4mg lorazepam IV and (b) EEG and clinical improvement 
following lorazepam IV.
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Figure 2. 
(a) EEG shows left LPDs in a comatose patient following cardiac arrest; patient receives 10 mg Diazepam IV 
and (b) EEG shows dramatic improvement following Diazepam IV; however the patient remains comatose 
(possible NCSE ?).
Epilepsy - Advances in Diagnosis and Therapy
10
Figure 3. 
(a) EEG shows evolving GPDs with triphasic morphology and (b) EEG demonstrates some improvement 
following Diazepam; however the patient remained comatose.
11
Nonconvulsive Status Epilepticus in Patients with Altered Mental Status Admitted to Hamad…
DOI: http://dx.doi.org/10.5772/intechopen.83580
Figure 4. 
(a) EEG shows predominantly left sided LPDs with triphasic morphology; 32 years old male given baclofen 
30 mg for spasticity the first day of admission; 2 days later he presented an altered mental status with “akinetic 
mutism”; patient was given 6 mg lorazepam IV bolus. (b) Dramatic improvement in EEG and clinical status 
following IV lorazepam ; patient recovered completely, started talking and moving around normally; he was 
found to have a moderate to severe renal impairment (responsible for baclofen intoxication ?).
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3.7 Refractory NCSE
Thirty-two percent of patients with NCSE (n = 21, m 13, f 8) suffered from 
refractory NCSE, defined as seizures lasting more than 60 minutes with failure of 
two ASDs [37]; they received the following treatment: midazolam IV (n = 10), pro-
pofol (n = 5), thiopental (n = 4), and fentanyl (n = 2). Fifty-seven percent (n = 12, 
m 8, f 4) survived; forty-three percent (n = 9, m 5, f 4) died with the following 
reasons: cardiac arrest (3), sepsis (3), ischemia (1), subarachnoid hemorrhage (1), 
and cerebral abscess (1). Only 33% (n = 7, m 4, f 3) recovered completely.
3.8 EEG patterns and location
EEG patterns recorded in the NCSE patients (n = 65): focal spike/sharp and wave >3/s 
in 43% (n = 28), generalized spike/sharp and wave >3/s in 28% (n = 18), GDPs, LPDs, 
continuous 2/s GPDs with triphasic morphology in 25% (n = 16), and multifocal spikes 
in 4% (n = 3); Figures 1–5 show NCSE EEGs cases before and after ASD treatment.
13
Nonconvulsive Status Epilepticus in Patients with Altered Mental Status Admitted to Hamad…
DOI: http://dx.doi.org/10.5772/intechopen.83580
EEG in NCSE patients who ultimately died (n = 20): 40% periodic patterns 
(n = 8), 30% continuous generalized spike/sharp and waves (n = 6), and 30% with 
focal spike/sharp and waves (n = 6). Fifty-two percent (n = 34) showed a continuous 
ictal pattern, and forty-three percent (n = 28) an intermittent/recurrent ictal pattern; 
five percent (n = 3) were not classified; forty-six percent (n = 30) showed a focal 
onset and 29% (n = 19) a generalized onset; twenty-five percent (n = 16) showed a 
periodic pattern; focal seizures originated from the temporal areas (55%) and from 
the frontal areas (31%). In the control group (n = 185), focal/generalized slowing was 
seen in 43% (n = 80) and slowing with some spike/sharp wave activity in 2% (n = 4).
4. Discussion
4.1 NCSE prevalence
In the current longitudinal prospective hospital-based study, we investigated the 
frequency of NCSE in patients with AMS admitted to Hamad Hospital, Doha, Qatar. 
The prevalence of NCSE among patients with AMS was 26% at our center that is 
compatible with previous similar studies (prevalence = 16–37%) (Table 6); these 
researchers used a similar design, with a parallel control group; however, most were 
retrospective, the cEEG recording duration often shorter or not mentioned. Five 
other authors from MENA’ s neighboring countries (mentioned in Section 1) also 
reported the prevalence of NCSE in patients with AMS; however, they used differ-
ent study designs, and therefore, those studies cannot be compared with our study.
4.2 NCSE outcome
NCSE is often associated with a poor outcome and a high mortality rate  
[9, 12, 13, 38]. In the current study, the mortality rate among patients with AMS and 
Figure 5. 
(a) (Comatose focal NCSE) 67 years old male comatose, following head injury. EEG shows abnormal fast activity 
starting in right fronto-temporal leads accompanied by abnormal eye movements and facial twitching. (b) The 
ictal fast activity spreads to the contralateral fronto-temporal leads; patient shows same clinical manifestations 
(discrete twitching of the left face); the abnormal electrical activity was continuous for more than 30 mn. (c) 
1 minute following 2 mg of lorazepam IV; patient remains comatose; EEG shows diffuse generalized slowing; no 
epileptiform activity; no clinical manifestations; survived with memory impairment and left hemiplegia.
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NCSE was 31%, while the mortality rate among those with AMS and without NCSE 
was only 19%; NCSE carried a poor prognosis. Only one author reported similar 
outcome in NCSE and controls [9]; however death was more common in NCSE 
(37%) than in controls (23%). As previously reported by Young et al. [27], the 
length of stay and age were statistically significantly associated with mortality in the 
NCSE group (Table 7). In addition, in the current study, among patients with AMS 
and NCSE, head injury and stroke were associated with bad clinical outcomes with 
regard to recovery (Table 8). Also, we observed a longer hospitalization for NCSE 
group than that in the controls that is compatible with previous reports [13, 15].
We agree with Claassen [14] that most patients showing early NCSE EEG fea-
tures (n = 13, =65%) did not achieve good outcome; we did not find any association 
between acute symptomatology and outcome as highlighted by Kang [39].
Patients with “periodic discharges” did not completely meet the EEG criteria for 
NCSE. In ICUs and cEEG monitoring units, these periodic EEG patterns are described 
as lying along an ictal–interictal continuum. There are convincing studies that these 
PDs, especially GPDs and LPDs, are strongly associated with NCSE and may be ictal 
[13, 15, 32, 40–45]; in fact, these EEG patterns have been found in patients with AMS, 
Variable OR 95% CI P value
Age 1.16 1.0–1.34 0.05
Length of stay 2.03 1.29–3.20 0.002
Cardiac arrest 3.27 0.07–153 0.55
Stroke 35.0 0.33–3629 0.14
Head injury 30.1 0.02–56,392 0.38
Note: Variables significant at univariate analysis and having adequate numbers were used for multivariate analysis.
Table 7. 
Multivariate logistic regression for mortality in NSCE.
Author 
(year)
Methods Duration 
of EEG 
recording
Patients 
with 
AMS (n)
Patients with 
NCSE (n) (%)
Outcome
Mesraoua 
et al. (2017) 
Current study
Prospective 72 hs (250) 65 (26) Response to ASDs: NCSE 45/65 
(69%); death: NCSE 20/65 (31%); 
death in controls: 35/185 (19%); 
complete recovery: NCSE 26/65 
(40%); controls 98/185 (53%); 
NCSE longer hospital stay than 
controls p < 0.02 (Table 5)
Laccheo et al. 
[38] (2015)
Prospective >24hs (170) 36 (21) Mortality 31% NCSE vs 14% in 
controls
Kurtz et al. 
[12] (2014)
Retrospective ? (154) NCSE/NCSs 
24 (16), PEDs 
45(29)
NCSs/NCSE independently 
associated with poor outcome 20% 
vs 3% controls, p = 0.039
Bottaro et al. 
[13] (2007)
Retrospective 20mn (124) 22 (18) NCSE significant association with 
mortality, longer hospitalization 
and poor outcome
Privitera et al. 
[9] (1994)
Prospective 30mn (198) 74 (37) Death was more common in NCSE 
(37%) compared to controls 
(23%)
Table 6. 
Current and previous studies on NCSE prevalence and outcome.
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some were evolving and some responded to benzodiazepines, as shown in Figures 1–4. 
Many studies reported that PDs carry a bad prognosis, and the final outcome depends 
mainly on the etiology of AMS [8, 18–20, 39]; in our study, 50% of patients with PDs 
died; they suffered from stroke, cardiac arrest, sepsis, or head injury. However, in 
multivariate logistic regression analysis, we did not find a correlation between these 
etiologies and mortality in patients with AMS and NCSE (Table 7). It seems that 
prognosis in NCSE depends on several factors (e.g., age, etiology, level of conscious-
ness, etc.) and cannot be based on EEG or any one factor alone [20, 42].
Finally, the outcome of refractory NCSE was very poor in our study; 9 out of 21 
patients (43%) with refractory NCSE died; this is much higher than that reported 
in a previous study (25%) [46]. However, in that study, 17% of refractory NCSE 
patients were in a vegetative state.
As reported previously, history of epilepsy/seizures could be a risk factor for 
NCSs/NCSE [12, 13, 38].
4.3 cEEG monitoring duration
The optimal length of cEEG monitoring in critically ill ICU patients with AMS 
is a controversial issue in the literature. In our study, majority (66%) of NCSE 
cases were detected during the first 3 hours of cEEG monitoring; this detection 
rate reached to 90% by 48 hours of monitoring. Various required cEEG monitoring 
durations have been suggested in the literature; 12–24 hours [8, 12, 19, 22], 72 hours 
[16, 18, 47], and finally 7–10 days [23]. A recent study reported that 1/5 of patients 
without early EEG epileptiform features develop them during 72 hours of cEEG 
monitoring [25]; Claassen et al. concluded that seizures are detected only in 87% of 
comatose patients compared to non-comatose patients (98%) in the first 48 hours 
of cEEG monitoring [14].
Based on the results from our study and review of the literature, and also consid-
ering the challenges and costs associated with cEEG monitoring, we suggest that 3 
days of cEEG monitoring is optimal in ICUs and in patients with AMS to detect the 
majority of cases of NCSs/NCSE [14, 25].
5. Conclusion
To our knowledge, this is the first prospective study reporting the prevalence of 
NCSE in Qatar, a small country in the MENA region. This figure (26%) was in the middle 
range. Patients with NCSE did not do better than the controls, the result being disap-
pointing regarding comatose NCSE. NCSE is an emerging condition requiring rapid 
diagnosis and rapid treatment. Regarding the duration of cEGG monitoring to diagnose 
the majority of NCSE cases, 3 days of cEEG monitoring could accomplish this task.
Variable OR 95% C.I. P value
Age 1.0 0.96–1.05 0.74
Length of stay 1.10 0.90–1.34 0.36
Cardiac arrest 4.22 0.64–27.9 0.14
Stroke 26.30 3.24–213 0.03
Head injury 19.5 1.30–293 0.002
Note: Variables significant at univariate analysis and having adequate numbers were used for multivariate analysis.
Table 8. 
Multivariate logistic regression for morbidity in NSCE.
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